GLP-1 receptor agonists for obesity: eligibility across 99 countries [0.03%]
99个国家中的肥胖症GLP-1受体激动剂适用性研究
Sang Gune K Yoo,Felix Teufel,Michaela Theilmann et al.
Sang Gune K Yoo et al.
Circadian and sleep medicine: challenges and future directions for metabolic and endocrine research [0.03%]
昼夜节律和睡眠医学：代谢和内分泌研究的挑战与未来方向
Thomas Marjot,Nan Yang,David W Ray
Thomas Marjot
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial [0.03%]
针对纯合子型家族性高胆固醇血症患者使用Zoladesiran（一种针对ANGPTL3的RNAi疗法）的二期开放标记、随机临床试验（GATEWAY）
Frederick J Raal,Jean Bergeron,Daniel Gaudet et al.
Frederick J Raal et al.
Background: ANGPTL3 plays a key part in lipoprotein metabolism. Zodasiran, a liver-targeted RNA interference therapeutic, inhibits ANGPTL3 expression and reduces atherogenic lipoproteins through mechanisms independent of ...
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement [0.03%]
持续葡萄糖监测和自动化胰岛素递送技术在1型、2型或妊娠期糖尿病孕产妇中应用的国际共识声明
Katrien Benhalima,Celeste Durnwald,Arianne Sweeting et al.
Katrien Benhalima et al.
Insulin resistance increases after the first trimester of pregnancy, leading to glycaemic challenges for women with pregestational type 1 diabetes or type 2 diabetes. Additionally, insulin resistance can promote hyperglycaemia in pregnant w...
Shivani A Patel,Ishaan Pathak,Roopa Shivashankar
Shivani A Patel